Fragmented scientific context
Target rationale, molecular evidence, development assumptions, QC and review decisions sit in disconnected tools and documents.
INDIA-FIRST · GLOBAL DRUG-DISCOVERY INFRASTRUCTURE
Close the loop from scientific decision to experimental evidence.
BayesPharma AI connects evidence, models, uncertainty and accountable decisions across drug development. BayesPharma Labs turns approved experimental intent into governed digital execution today—and qualified physical execution in earned stages.
Truth boundary: software and Digital Twin capabilities are live; public experimental outputs are simulated, not measured. No commissioned BayesPharma physical robotic laboratory is claimed today.
01 / THE INVESTMENT THESIS
Drug R&D has powerful tools—but a broken decision-to-evidence loop.
Evidence lives across papers, models, specialist software, CRO reports and laboratory systems. Context and uncertainty are lost at handoffs, while model output can be mistaken for experimental proof. BayesPharma is building the operating layer that preserves the scientific chain and makes every next action reviewable.
Prediction without evidence discipline
AI can increase output volume faster than teams can validate provenance, uncertainty, applicability and scientific authority.
A compounding evidence loop
Connect decisions to experiments and outcomes so programme history becomes a reusable operational learning asset.
02 / THE PRODUCT
One evidence spine. Two operating layers.
The system is designed around the next accountable decision—not around a single model, chatbot or robot.
Scientific intelligence across the development lifecycle.
Connect target biology, therapeutic design, screening, lead optimization, DMPK, toxicology, MIDD, clinical development, statistics and regulatory evidence.
Open BayesPharma AI / Innovator →Governed digital laboratory execution.
Compile experimental intent into signed protocols, validate in a Digital Twin, schedule virtual devices, inject and recover from faults, run QC and preserve evidence provenance.
Inspect the Digital Autonomous Laboratory →QUESTIONProgramme context
→EVIDENCEBiology + prior work
→AI / MODELSDesign + computation
→DECISIONHuman authority
→EXPERIMENTGoverned execution
→LEARNUpdate programme
03 / PROOF TODAY
Build the control plane before buying the hardware.
The current product proves software architecture, scientific boundaries and digital execution. The next financing milestone is measured experimental validation and repeatable commercial proof.
Innovator
- Discovery-to-development workflow surfaces
- Evidence and review context
- Model-informed development tools
- Scientific limitations made visible
Digital Lab
- Signed protocol compilation
- Digital Twin validation
- Virtual device orchestration
- Fault injection and rerouting
- QC and provenance
Mission Control
- Programme and run state
- Devices and workcells
- QC deviations
- Evidence and audit trail
- One autonomy source of truth
CURRENT EVIDENCE CLASSSoftware functionality is demonstrable. Digital Twin results remain SIMULATED_NOT_MEASURED. Physical instruments: 0 commissioned.Open Mission Control →
04 / MARKET CONTEXT
Three growing spend pools converge around the BayesPharma thesis.
These external categories overlap and are deliberately not added together. The TAM calculation below uses only the drug-discovery-services market as a conservative anchor.
Projected to US$12.56B by 2034; 12.2% CAGR. Software is the dominant segment.
Fortune Business Insights ↗Projected to US$27.23B by 2030; 10.7% CAGR. Hit-to-lead is the leading process segment.
MarketsandMarkets ↗Projected to US$20.71B by 2034; 9.43% CAGR across devices, software and accessories.
Fortune Business Insights ↗Source dates: MarketsandMarkets, March 2025; Fortune Business Insights AI in Drug Discovery, accessed August 2026; Fortune Business Insights Laboratory Automation, updated August 3, 2026.
05 / TAM · SAM · SOM
A conservative market model investors can recalculate.
No category stacking. No claim that total pharmaceutical R&D spend is addressable. Every management assumption is visible.
Global drug-discovery services, 2025
External top-down anchor covering target selection through candidate validation, chemistry and biology services.
Reported market sizeSoftware + managed-discovery beachhead
Management model for emerging biotech, mid-market pharma, CROs and translational groups reachable through a software-first offer.
3,000 target organisations × US$150k blended annual valueAnnual revenue capture scenario
A base-case operating target, not a promised forecast or valuation input.
75 enterprise accounts × US$160k + 24 campaigns × US$250kWHY THIS SAM IS SMALLER
It excludes large portions of wet-lab outsourcing, diagnostics automation, hardware sales, manufacturing, clinical CRO spend and the wider pharmaceutical market.
WHAT CHANGES IT
Validated physical workcells, enterprise security, measured evidence, additional modalities and expansion into MIDD/clinical decision workflows can widen the serviceable market.
HOW TO READ SOM
It is a market-capture scenario used to test commercial plausibility. It is not current ARR, contracted backlog or a guaranteed five-year projection.
06 / BUSINESS MODEL
Land with a decision workflow; expand into programmes and execution.
Pricing is structured around accountable scientific value, programme scope and execution complexity—not token consumption.
US$24k–60k / year
Focused workflows, bounded users, pilot support and evidence exports.
LandUS$100k–300k / year
Private programmes, governance, integrations, assurance and broader lifecycle workflows.
Recurring softwareUS$75k–250k / campaign
Target readiness, virtual screening, prioritization, evidence packages and CRO handoff.
Services + softwareUS$150k–500k / year
Qualified workcells, adapters, scheduling, QC, recovery and evidence provenance.
ExpandGROSS-MARGIN TARGET75–85% software35–55% managed programmes; 60–70% blended at scale
BUYERDiscovery / translational leadershipR&D operations, computational chemistry, clinical pharmacology
SALES MOTIONPaid pilot → enterprise expansionExpected 3–9 month cycle; partner-led entry where useful
Pricing, margins and sales-cycle ranges are management targets for planning; they are not current contracted metrics.
07 / GO-TO-MARKET
A narrow commercial wedge into a much larger workflow.
Evidence-to-decision pilot
Start with one high-value decision: target readiness, candidate prioritization, DMPK/MIDD review or development evidence gap.
Managed discovery campaign
Extend into a bounded programme with auditable computation, candidate evidence and qualified CRO handoff.
Enterprise operating layer
Expand across programmes, teams, integrations and—after qualification—experimental execution.
Teams with real programmes but fragmented specialist tooling and limited internal platform engineering.
Connect BayesPharma decisions to measured work without claiming an owned physical lab before it exists.
Use India’s pharma/CRO network as an operating advantage while selling a globally relevant scientific product.
Grow within the same programme as its evidence and decisions advance.
08 / COMPETITIVE LANDSCAPE
BayesPharma connects categories that are usually purchased separately.
Representative companies are shown by primary emphasis, not as claims that their capabilities are limited to one column.
| Category | Representative companies | Primary strength | BayesPharma position |
|---|---|---|---|
| AI-native discovery | Recursion / Exscientia, Insilico Medicine | Model-led target and molecule discovery | Evidence-to-decision continuity across lifecycle workflows, plus a governed lab-control plane and India-first execution strategy.Positioning thesis—not a claim of feature exclusivity. |
| Scientific software | Schrödinger, Dotmatics, Benchling | Specialist computation, data and R&D informatics | |
| MIDD / regulatory | Certara | Model-informed development and regulatory software/services | |
| Discovery CRO / CRDMO | Syngene, Aragen, Charles River | Measured chemistry, biology and outsourced execution | |
| Automated / cloud labs | Emerald Cloud Lab and automation vendors | Remote or instrument-level experimental automation |
Evidence lineage
Inputs, assumptions, model context, uncertainty and reviewers remain attached to decisions.
Lifecycle continuity
Discovery, translation, MIDD, clinical and statistics share programme context.
Control-plane IP
Protocol compilation, policy, scheduling, recovery and QC create an execution architecture.
Compounding history
Decisions plus experimental outcomes can become proprietary operational data.
09 / WHY INDIA · WHY NOW
India’s pharma scale can become an innovation advantage.
India has deep chemistry, manufacturing, generics, CRO/CRDMO capability and scientific talent. The strategic opening is to connect those strengths with AI, accountable evidence and automation.
Build globally relevant drug-discovery infrastructure from India—while capital follows earned technical proof.
10 / 24-MONTH PLAN
Convert software proof into commercial and measured-evidence proof.
Product hardening
Security, tenant boundaries, scientific assurance, reliability and pilot packaging.
Target: 3 paid pilotsMeasured validation
CRO-linked experiments, evidence ingestion and design–test–learn validation.
Target: 2 measured loopsRepeatable selling
Reference workflows, enterprise integrations and partner channels.
Target: 8 paying organisationsFirst qualified workcell
Lab Edge plus liquid-handling and reader adapters behind safety/QC gates.
Target: 1 qualified workcellMilestones are forward-looking management targets. They are not current traction or guaranteed outcomes.
11 / TEAM
Founder-market fit with a deliberately staged hiring plan.
B
FOUNDER
Gunda Upendar Rao
Pharmaceutical-science-trained founder building across drug development, scientific software and autonomous R&D. His work combines domain depth with hands-on product creation and an India-first mission.
B.Pharm · UCPSC, Kakatiya UniversityNIPER Mohali · 2010–2012GPAT / AICTE 2010 · AIR 5Pharma × technology × scientific product
Founder profile on LinkedIn →Head of Drug Discovery
Translational biology, chemistry strategy and programme governance.
Platform / AI engineering lead
Enterprise architecture, security, model operations and integrations.
Lab automation lead
Device qualification, controls, safety, QC and workcell commissioning.
Clinical + regulatory network
MIDD, toxicology, regulatory science, IP and commercial partnering.
12 / PROPOSED PRE-SEED
₹12 crore to reach measured proof and repeatable commercial proof.
A 24-month financing plan that earns physical automation rather than front-loading a large robotic facility.
PROPOSED RAISE₹12 Cr24-month plan
Product + engineering
Enterprise hardening, reliability, security, integrations and scientific assurance.
CRO + validation
Measured experiments, reference datasets, assay work and evidence-loop proof.
Commercial
Pilot delivery, partnerships, customer success and focused global selling.
First workcell
Lab Edge, qualified liquid handling, reader integration and safety systems.
Operations + governance
IP, legal, regulatory, finance, quality systems and contingency.
Raise amount, allocation and runway are management proposals for investor discussion and remain subject to diligence, financing terms and detailed operating budgets.
13 / INVESTOR DILIGENCE
The important risks are visible—and designed into the plan.
Models may not translate
Mitigation: measured partner experiments, explicit applicability limits and human decision gates.
Enterprise cycles are long
Mitigation: paid bounded pilots, high-value workflow wedges and partner-led selling.
Physical labs can consume cash
Mitigation: software-first architecture; buy hardware only after qualified demand and evidence.
Client boundaries must be absolute
Mitigation: isolated programmes, provenance, access control and explicit data-use agreements.
AI outputs require context
Mitigation: risk-based credibility, auditability, stated context of use and human authority.
The team must broaden
Mitigation: staged scientific, engineering and automation leadership hires plus advisors.
Diligence pack to provide under NDACorporate structure + cap tableIP assignmentsDetailed 24-month budgetProduct/security architectureCRO validation planCustomer pipeline and references
14 / SOURCES + METHODOLOGY
Every market claim has a boundary.
US$16.36B in 2025; US$27.23B by 2030; 10.7% CAGR.
MarketsandMarkets, March 2025 ↗US$5.00B in 2026; US$12.56B by 2034; 12.2% CAGR.
Fortune Business Insights ↗US$10.07B in 2026; US$20.71B by 2034; 9.43% CAGR.
Fortune Business Insights, updated Aug 2026 ↗India pharma, CRDMO and Biopharma SHAKTI market and policy context.
India Brand Equity Foundation, Feb 2026 ↗FDA notes increasing AI use across nonclinical, clinical, postmarketing and manufacturing phases.
U.S. FDA ↗Market reports use different scopes and methodologies. BayesPharma does not add overlapping category estimates. SAM, SOM, pricing, margins, milestones and use of funds are management assumptions dated August 22, 2026 and should be tested during diligence.
BAYESPHARMA
AI → Experiment → Evidence → Learning → Novel Medicine
Software proof now. Measured proof next. Physical automation only when earned.
Investor briefing · BayesPharma · Hyderabad, India · Updated August 22, 2026